Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11377840 | PMC |
| http://dx.doi.org/10.1681/ASN.0000000000000432 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Major Adverse Kidney Events in Hospitalized Older Patients With Acute Kidney Injury: Machine Learning-Based Model Development and Validation Study.
J Med Internet Res
January 2025
Department of Nephrology, Hunan Key Laboratory of Kidney Disease and Blood Purification, The Second Xiangya Hospital of Central South University, Changsha, China.
Background: Acute kidney injury (AKI) is a common complication in hospitalized older patients, associated with increased morbidity, mortality, and health care costs. Major adverse kidney events within 30 days (MAKE30), a composite of death, new renal replacement therapy, or persistent renal dysfunction, has been recommended as a patient-centered endpoint for clinical trials involving AKI.
Objective: This study aimed to develop and validate a machine learning-based model to predict MAKE30 in hospitalized older patients with AKI.
pyAKI-An open source solution to automated acute kidney injury classification.
PLoS One
January 2025
Department of Anaesthesiology, Intensive Care and Pain Medicine, University Hospital Müunster, Müunster, Germany.
Objective: Acute kidney injury (AKI) is a frequent complication in critically ill patients, affecting up to 50% of patients in the intensive care units. The lack of standardized and open-source tools for applying the Kidney Disease Improving Global Outcomes (KDIGO) criteria to time series, requires researchers to implement classification algorithms of their own which is resource intensive and might impact study quality by introducing different interpretations of edge cases. This project introduces pyAKI, an open-source pipeline addressing this gap by providing a comprehensive solution for consistent KDIGO criteria implementation.
View Article and Find Full Text PDFSystematic review and meta-analysis of randomized controlled trials comparing the clinical outcomes of SARS-CoV-2 and influenza in pediatric patients.
Adv Clin Exp Med
January 2025
School of Medicine, Hunan Polytechnic College of Environment and Biology, Hengyang, China.
Only a few studies have examined the effects of coronavirus disease 2019 (COVID-19) and influenza on clinical outcomes in pediatric patients. Furthermore, no meta-analysis has assessed the impact of these diseases on adverse outcomes. This study aims to compare the clinical outcomes of COVID-19 and influenza in pediatric patients.
View Article and Find Full Text PDFNirmatrelvir/ritonavir is a novel drug combination authorized by the US Food and Drug Administration for the treatment of coronavirus disease 2019 (COVID-19). This report describes the case of a patient with a prior history of kidney transplantation who received nirmatrelvir/ritonavir. In this case, sirolimus use was successfully stopped before nirmatrelvir/ritonavir treatment, and the nirmatrelvir/ritonavir trough concentration was determined.
View Article and Find Full Text PDFSnakebite envenomation-associated acute kidney injury: a South-Asian perspective.
Trans R Soc Trop Med Hyg
January 2025
Department of Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry 605006, India.
Snakebite is a neglected public health problem in tropical countries. Snakebite envenomation-associated acute kidney injury (SBE-AKI) is a major complication accounting for significant morbidity and mortality. The pathogenesis of SBE-AKI may be multifactorial, including prerenal AKI secondary to hemodynamic alterations, intrinsic renal injury, immune-related mechanisms, venom-induced consumptive coagulopathy and capillary leak syndrome.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!